CNS is a strategically important therapeutic area and Synexus has the specialist experience with pain study conduct and the capacity and resource to conduct psychiatry studies. With over 1,500 patients recruited in 47 studies and 89% of the Synexus patient community aged 50 and over, there is a strong source of older patients who represent ideal candidates for cognitive health. These studies are being developed to identify patients for early cognitive impairments.

Our global leadership in schizophrenia is well known throughout industry and academia. We support numerous clinical and neurocognitive endpoints, including assessment of at-risk status, conversion to psychosis, and functional capacity. We also support clinical development programs in bipolar disorder, major depressive disorder, post-traumatic stress disorder, attention-deficit disorder, and other conditions affecting mental health and cognition.

Areas of expertise include

  • Alcohol dependancy
  • Alzheimer's disease
  • Anxiety
  • Depression
  • Early cognitive impairment screening
  • Insomnia
  • Migraine
  • Neuralgia
  • Neuropathic pain
  • Pain - knees and hips
  • Pain - lower back
  • Parkinson's disease
  • Restless Leg Syndrome
  • Sexual dysfunction
  • Smoking cessation
  • Tinnitus

Approaching

24K

CNS patients randomised

CNS studies

897

performed

Synexus patient community

89%

aged 50 and over